Glycopyrrolate

Glycopyrronium bromide

Clinical data
Trade names	Robinul (tablets, intravenous), Seebri (inhalation), others
Pregnancy category	US: B (No risk in non-human studies)
ATC code	A03AB02 (WHO) R03BB06 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name 3-[2-Cyclopentyl(hydroxy)phenylacetoxy]-1,1-dimethylpyrrolidinium bromide
CAS Number	51186-83-5 Y
PubChem CID	11693
ChemSpider	11201
UNII	V92SO9WP2I
ECHA InfoCard	100.008.990
Chemical and physical data
Formula	C19H28BrNO3
Molar mass	398.335 g/mol
3D model (Jmol)	Interactive image
SMILES C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
InChI InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1 Key:VPNYRYCIDCJBOM-UHFFFAOYSA-M

Glycopyrronium

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a602014
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	By mouth, intravenous, inhalation
ATC code	A03AB02 (WHO) R03BB06 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Biological half-life	0.6–1.2 hours
Excretion	85% renal, unknown amount in the bile
Identifiers
IUPAC name 3-(2-Cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium
CAS Number	596-51-0 Y
PubChem CID	3494
IUPHAR/BPS	7459
DrugBank	DB00986 Y
ChemSpider	3374
UNII	V92SO9WP2I
KEGG	D00540 Y
ChEMBL	CHEMBL1201335 N
ECHA InfoCard	100.008.990
Chemical and physical data
Formula	C19H28NO3+
Molar mass	318.431 g/mol
3D model (Jmol)	Interactive image
SMILES C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C
InChI InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1 Key:ANGKOCUUWGHLCE-UHFFFAOYSA-N
NY (what is this?)

Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has no to few central effects. A synthetic quaternary amine, it is available in oral and intravenous forms and as inhalation. It was developed by Sosei and licensed to Novartis in 2005. The cation, which is the active moiety, is called glycopyrronium (INN) or glycopyrrolate (USAN).

In anesthesia, glycopyrronium injection can be used as a preoperative medication in order to reduce salivary, tracheobronchial, and pharyngeal secretions, as well as decreasing the acidity of gastric secretion. It is also used in conjunction with neostigmine, a neuromuscular blocking reversal agent, to prevent neostigmine's muscarinic effects such as bradycardia.

It is also used to reduce excessive saliva (sialorrhea), and Ménière's disease.

It decreases acid secretion in the stomach and so may be used for treating stomach ulcers, in combination with other medications.